유럽 연합 - 노르웨이어 - EMA (European Medicines Agency)

astrazeneca ab - olaparib - ovarie neoplasmer - antineoplastiske midler - ovarian cancerlynparza er indisert som monoterapi for:vedlikehold behandling av voksne pasienter med avansert (figo stadier iii og iv) brca1/2-muterte (germline og/eller somatiske) high-grade epithelial ovarian, fallopian tube eller primære peritoneal kreft som er i respons (hel eller delvis) etter gjennomføring av første-linje platinum-basert kjemoterapi. maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy. lynparza in combination with bevacizumab is indicated for the:maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability (see section 5. breast cancerlynparza is indicated as:monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline brca1/2-mutations who have her2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4. 2 og 5. monotherapy for the treatment of adult patients with germline brca1/2-mutations, who have her2 negative locally advanced or metastatic breast cancer. pasienter bør ha tidligere blitt behandlet med en anthracycline og en taxane i (neo)adjuvant eller metastatisk innstillingen med mindre pasienter ikke var egnet for disse behandlingene (se punkt 5.. pasienter med hormon-reseptor (hr)-positiv brystkreft bør også ha utviklet seg på eller etter forutgående endokrin terapi, eller anses som uegnet for endokrin terapi. adenocarcinoma of the pancreaslynparza is indicated as:monotherapy for the maintenance treatment of adult patients with germline brca1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen. prostate cancerlynparza is indicated as:monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc) and brca1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent. in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mcrpc in whom chemotherapy is not clinically indicated (see section 5.

노르웨이 - 노르웨이어 - Statens legemiddelverk

ge healthcare ltd - krom (51cr) edetat - injeksjonsvæske, oppløsning - 3.7 mbq/ ml

노르웨이 - 노르웨이어 - Statens legemiddelverk

curium netherlands b.v. - indium (111in) oksin - oppløsning - 37 mbq/ ml

노르웨이 - 노르웨이어 - Statens legemiddelverk

curium netherlands b.v. - natriummolybdat mo-99 omdannet til natriumperteknetat tc-99m - radionuklidegenerator

노르웨이 - 노르웨이어 - Statens legemiddelverk

ge healthcare b.v. - jobenguansulfat (123i) - injeksjonsvæske, oppløsning - 74 mbq/ ml

노르웨이 - 노르웨이어 - Statens legemiddelverk

eli lilly norge as - insulin - injeksjonsvæske, suspensjon - 100 ie/ ml

노르웨이 - 노르웨이어 - Statens legemiddelverk

eli lilly norge as - insulin - injeksjonsvæske, suspensjon - 100 ie/ ml

노르웨이 - 노르웨이어 - Statens legemiddelverk

elanco gmbh - aeromonas salmonicida, hel, inaktivert / vibrio anguillarum, serotype o1, inaktivert / vibrio anguillarum, serotype o2a, inaktivert / aliivibrio salmonicida, inaktivert / moritella viscosa, inaktivert / pankreasnekrosevirus, infeksiøs, inaktivert - injeksjonsvæske, emulsjon

노르웨이 - 노르웨이어 - Statens legemiddelverk

ge healthcare buchler gmbh & co. kg - natriumjodid (131i) - kapsel, hard - 3.7 mbq

노르웨이 - 노르웨이어 - Statens legemiddelverk

ge healthcare buchler gmbh & co. kg - tauroselkolsyre - kapsel, hard - 370 kbq